ST吉药(300108) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥71,621,163.94, a decrease of 39.31% compared to ¥118,015,687.61 in the same period last year[5] - The net loss attributable to shareholders was ¥20,231,788.56, an improvement of 61.20% from a loss of ¥52,149,950.90 in the previous year[5] - The net loss for the quarter was ¥30,964,687.78, an improvement of 40.7% compared to a net loss of ¥52,275,394.38 in the same period last year[17] - The company's basic and diluted earnings per share were both -¥0.0304, showing a 61.17% improvement from -¥0.0783 in the same period last year[5] - The company reported a gross profit margin of approximately -77.5% for the quarter, indicating significant operational challenges[16] Cash Flow and Liquidity - The net cash flow from operating activities was negative at ¥6,914,375.11, a decline of 277.39% compared to a positive cash flow of ¥3,897,872.36 in the same period last year[5] - Cash flow from operating activities showed a net outflow of ¥6,914,375.11, contrasting with a net inflow of ¥3,897,872.36 in the previous year[18] - Cash and cash equivalents decreased significantly from CNY 29,955,789.96 to CNY 16,720,883.29, a drop of about 44%[13] - Cash and cash equivalents at the end of the period were ¥11,732,220.95, compared to ¥5,998,060.27 at the end of the previous period, reflecting an increase of 95.5%[20] - The company experienced a net cash outflow from financing activities of ¥4,410,387.77, compared to a larger outflow of ¥11,848,594.83 in the previous year[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,134,579,534.76, down 3.95% from ¥2,222,263,244.50 at the end of the previous year[5] - The total current assets decreased from CNY 540,104,453.27 at the beginning of the year to CNY 517,875,364.26 at the end of the period, representing a decline of approximately 4.3%[13] - Total liabilities decreased from CNY 2,588,572,723.56 to CNY 2,519,558,065.17, reflecting a decline of about 2.7%[14] - The total non-current assets decreased from CNY 1,682,158,791.23 to CNY 1,616,704,170.50, a decline of approximately 3.9%[14] Equity and Retained Earnings - The total equity attributable to shareholders decreased by 26.32% to ¥56,627,299.35 compared to the previous year-end[5] - The total equity attributable to shareholders of the parent company decreased from CNY 76,859,087.91 to CNY 56,627,299.35, a decline of about 26.3%[15] - The company reported a net loss in retained earnings, increasing from CNY -2,226,915,121.89 to CNY -2,247,146,910.45[15] Operational Performance - The company reported a significant decrease in sales revenue due to a decline in domestic and export volumes of downstream products in the chemical sector[8] - Total operating costs amounted to ¥127,061,747.57, down 22.5% from ¥163,961,790.14 year-over-year[16] - Research and development expenses were ¥2,099,855.68, down 33.9% from ¥3,174,932.13 in the previous year[16] - The company incurred financial expenses of ¥37,287,430.41, slightly down from ¥37,711,830.27 year-over-year[16] Government Support - The company received government subsidies amounting to ¥38,440.44, which are closely related to its normal business operations[6]